FIELD: medicine, oncology. SUBSTANCE: invention proposes to the of use relanium (diazepam) in the dose 5 mg, three times per a day for 7 days. Invention can be used for correction of immunological status of patients with lung cancer. EFFECT: enhanced effectiveness of lung cancer immunotherapy. 1 tbl
Authors
Dates
2001-05-27—Published
1998-11-16—Filed